(2S)-(+)-chromane-2-carboxamide | 850848-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (2S)-(+)-chromane-2-carboxamide
• 英文别名: (2S)-3,4-dihydro-2H-1-benzopyran-2-carboxamide；(2S)-3,4-dihydro-2H-chromene-2-carboxamide
• CAS: 850848-20-3
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: AFYJYAWBTFNDAN-VIFPVBQESA-N

物化性质

• 沸点：
  397.5±32.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2S)-(+)-chromane-2-carboxamide 在 diborane(6) 作用下， 以 四氢呋喃 为溶剂， 以86%的产率得到(2S)-(+)-3,4-dihydro-2H-chromen-2-ylmethylamine
  参考文献：
  名称：

  New Serotonin 5-HT_1A Receptor Agonists with Neuroprotective Effect against Ischemic Cell Damage

  摘要：

  We report the synthesis of new compounds 4 35 based on structural modifications of different moieties of previously described lead UCM-2550. The new nonpiperazine derivatives, representing second-generation agonists, were assessed for binding affinity, selectivity, and functional activity at the 5-HT1A receptor (5-HT1AR). Computational beta(2)-based homology models of the ligand receptor complexes were used to explain the observed structure affinity relationships. Selected candidates were also evaluated for their potential in vitro and in vivo neuroprotective properties. Interestingly, compound 26 (2-{6-[(3,4:-dihydro-2H-chromen-2-ylmethyl)amino]hexyl}-tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione) has been characterized as a high-affinity and potent 5-HT1AR agonist (K-i, = 5.9 nM, EC50 = 21.8 nM) and exhibits neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in the MCAO model of focal cerebral ischemia in rats.

  DOI：

  10.1021/jm2007886
• 作为产物：
  描述：

  (S)-chroman-2-carboxylic acid 在 硫酸 、 氨 、 氯化铵 作用下， 以 水 为溶剂， 反应 4.0h， 生成 (2S)-(+)-chromane-2-carboxamide
  参考文献：
  名称：

  New Serotonin 5-HT_1A Receptor Agonists with Neuroprotective Effect against Ischemic Cell Damage

  摘要：

  We report the synthesis of new compounds 4 35 based on structural modifications of different moieties of previously described lead UCM-2550. The new nonpiperazine derivatives, representing second-generation agonists, were assessed for binding affinity, selectivity, and functional activity at the 5-HT1A receptor (5-HT1AR). Computational beta(2)-based homology models of the ligand receptor complexes were used to explain the observed structure affinity relationships. Selected candidates were also evaluated for their potential in vitro and in vivo neuroprotective properties. Interestingly, compound 26 (2-{6-[(3,4:-dihydro-2H-chromen-2-ylmethyl)amino]hexyl}-tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione) has been characterized as a high-affinity and potent 5-HT1AR agonist (K-i, = 5.9 nM, EC50 = 21.8 nM) and exhibits neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in the MCAO model of focal cerebral ischemia in rats.

  DOI：

  10.1021/jm2007886

文献信息

• VERFAHREN ZUR HERSTELLUNG VON ENANTIOMERENREINEN, IN 2-POSITION SUBSTITUIERTEN CHROMANDERIVATEN
  申请人：Merck Patent GmbH

  公开号：EP1673362A2

  公开（公告）日：2006-06-28
• [DE] VERFAHREN ZUR HERSTELLUNG VON ENANTIOMERENREINEN, IN 2-POSITION SUBSTITUIERTEN CHROMANDERIVATEN<br/>[EN] METHOD FOR PRODUCING CHROMANE DERIVATIVES THAT ARE DEVOID OF ENANTIOMERS AND ARE SUBSTITUTED IN POSITION 2<br/>[FR] PROCEDE DE PRODUCTION DE DERIVES DE CHROMANE SUBSTITUES EN POSITION 2, EXEMPTS D'ENANTIOMERES
  申请人：MERCK PATENT GMBH

  公开号：WO2005037817A2

  公开（公告）日：2005-04-28

  Die Erfindung betrifft ein Verfahren zur Herstellung von enantiomerenreinen, an der 2-Position substituierten Chromanderivaten aus den entspre­chenden enantiomerenreinen Chroman-2-Carbonsäureestern.